Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer.
Connolly R, Jankowitz R, Zahnow C, Zhang Z, Rudek M, Slater S, Powers P, Jeter S, Brufsky A, Piekarz R, Herman J, Ahuja N, Somlo G, Garcia A, Baylin S, Davidson N, Stearns V. Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer. Journal Of Clinical Oncology 2014, 32: 569-569. DOI: 10.1200/jco.2014.32.15_suppl.569.Peer-Reviewed Original Research